OXAZOLINE DERIVATIVES FOR TREATING CNS DISORDERS Russian patent published in 2015 - IPC C07D263/28 C07D413/12 C07D413/14 C07D417/12 C07D471/04 A61K31/421 A61K31/423 A61K31/427 A61K31/4709 A61K31/4427 A61K31/5377 A61P25/00 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a compound of formula

wherein R^a represents hydrogen or C_1-7alkyl; R¹ represents groups and or may be specified in a group consisting of , wherein R⁸ represents hydrogen, halogen or aryl optionally substituted by halogen; X represents a bond, -(CH₂)_n-, -CHRCH₂-, -CHR(CH₂)₂-, -O-CHRCH₂- or -(C₃cyclopropyl)-CH₂-CH₂-, and R represents C_1-7alkyl or C_1-7alkyl substituted by halogen; R² represents a) C_1-7alkyl; b) hydrogen; c) NH-phenyl optionally substituted by one or more substitutes specified in halogen or C_1-7alkyl substituted by halogen; d) NH-6-merous heteroaryl containing 1 or 2 heteroatoms N optionally substituted by one or more substitutes specified in halogen or C_1-7-alkyl substituted by halogen; e) (CR'R")_m-C_3-6-cycloalkyl optionally substituted by halogen, C_1-7alkyl, C_1-7alkyl substituted by halogen, halogen-substituted phenyl or heteroaryl, which represents pyridine; f) 6-merous heterocycloalkyl containing 1 or 2 heteroatoms specified in N and O, optionally substituted by halogen or C_1-7alkyl substituted by halogen; g) (CR'R")_m-5-6-merous monocyclic or 9-10-mrous bicyclic heteroaryl containing 1-3 heteroatoms specified in N, S and O, optionally substituted by halogen, C_1-7alkoxy, C_1-7alkyl, substituted by halogen, C_1-7alkoxy substituted by halogen, C_1-7alkyl, C_3-6-cycloalkyl, NHC(O)-C_1-7alkyl, cyano, S(O)₂-C_1-7alkyl, NR⁶R⁷ or 5-6-merous heteroaryl containing 1 or 2 heteroatoms, N or 6-merous heterocyclyl containing 1 or 2 heteroatoms specified in N, O and S, wherein S is optionally specified by two oxygen molecules, which is optionally substituted by halogen; h) (CR'R")_m-phenyl optionally substituted by halogen, C_1-7alkyl substituted by halogen, C_1-7-alkoxy substituted by halogen, C_1-7alkyl, C_2-7alkinyl, C_1-7alkoxy, CH₂-C_1-7alkoxy or cyano; i) -O(CH₂)_o-phenyl optionally substituted by halogen, C_1-7alkoxy or C_1-7alkyl substituted by halogen; R' and R" independently represent hydrogen, C_1-7alkoxy or C_1-7alkyl; or together with atom C may form C_3-6-cycloalkyl group; R³ represents phenyl or 10-merous heteroaryl containing 1 heteroatom N, wherein the above aromatic rings are optionally substituted by one or more substitutes specified in halogen or C_1-7alkoxy; R⁴ represents C_1-7alkyl, phenyl or 6-merous heteroaryl containing 1 heteroatom N, wherein the above aromatic rings are optionally substituted by one or more substituted specified in halogen, cyano or C_1-7alkoxy; R⁵ represents hydrogen, C_1-7alkyl or phenyl substituted by halogen; R⁶/R⁷ independently represent hydrogen, C_1-7alkyl or (CH₂)₂-O-C_1-7alkyl; m equals to 0, 1 or 2; n equals to 1, 2 or 3; o equals to 0 or 1; p equals to 0, 1 or 2; or their pharmaceutically acceptable acid addition salt. The invention also refers to compounds which represent 4-[2-((S)-2-amino-4,5-dihydrooxazol-4-yl)-ethyl]-N-(4-chlor-phenyl)-benzamide or (S)-4-(2-(2-amino-4,5-dihydrooxazol-4-yl)-ethyl)-N-(5-ethynylpyridin-2-yl)benzamide. The compositions according to the invention are applicable to produce a pharmaceutical composition having a high affinity to trace amine associated receptors.

EFFECT: oxazoline derivatives applicable in treating depression, bipolar disorder, attention deficit/hyperactivity syndrome (ADHD), psychotic disorders, schizophrenia, Parkinson's disease, migraine and addictive substance abuse.

23 cl, 1 tbl, 233 ex